Advanced Combination Therapy with Biologics and Upadacitinib in Refractory Inflammatory Bowel Disease: A Retrospective Study from Taiwan
This is the first study in Asia to demonstrate that UPA-based ACT is both effective and safe in treating refractory IBD. However, the limitations of this retrospective, single-center study with a relatively small sample size highlight the need for future larger-scale, multi-center prospective studies to confirm these findings, identify predictors of treatment response, and evaluate long-term outcomes.
Authors
- Cheng‐Tang Chiu (ORCID: https://orcid.org/0000-0002-7437-8052)
- Ming‐Yao Su (ORCID: https://orcid.org/0000-0002-5229-3074)
- Puo‐Hsien Le (ORCID: https://orcid.org/0000-0002-1100-5371)
- Chia‐Jung Kuo (ORCID: https://orcid.org/0000-0003-2845-6248)
- Ming-Ling Chang (ORCID: https://orcid.org/0000-0003-1958-5005)
Institutions
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Taipei Municipal YangMing Hospital (TW)
- Chang Gung Children's Hospital (TW)
Publication Details
- Journal
- Journal of Inflammation Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/jir.s511309
- Citations
- 6
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 10.90
Funders
- Chang Gung Medical Foundation
- Chang Gung Memorial Hospital, Linkou